



ASX RELEASE
29 May 2013

Novogen Announces SPP Outcome

Novogen today announced the raising of \$789,685 through the issue of 4,645,207 shares to current Australian and New Zealand Novogen shareholders under a Share Purchase Plan.

Dr Graham Kelly, CEO, said, "I am delighted that so many shareholders continue to have enough faith in the Company to subscribe to this share offering. These funds, combined with the \$2.4M we raised through a recent placement, give us sufficient funds to continue with our R&D program for CS-6 with the goal of bringing it into the clinic within 12 months as a treatment for late-stage glioblastoma (brain cancer) and ovarian cancer."

"Two other candidate compounds have been identified, and their development will depend on raising additional capital when we feel that market conditions are appropriate. Our long-term goal is to be the pre-eminent company globally in the area of personalised chemotherapy for many cancers. For that, we need a range of drugs that are active against both differentiated and undifferentiated (stem) cancer cells. Attaining that goal will depend on accelerating the development of those two new compounds along with screening the new libraries of super-benzopyran drugs currently under development in Switzerland,' Kelly added.

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA

PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA

E: Graham.Kelly@novogen.com

Further information is available on the Company's web site, www.novogen.com